Adjunctive Therapies to Optimize Closed-loop Glucose Control
Closed-loop insulin delivery systems are fast becoming the standard of care in the management of type 1 diabetes and have led to significant improvements in diabetes management. Nevertheless, there is still room for improvement for the closed-loop systems to optimize treatment and meet target glycem...
Gespeichert in:
| Veröffentlicht in: | Journal of diabetes science and technology 2021-11, Vol.15 (6), p.1243-1251 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1251 |
|---|---|
| container_issue | 6 |
| container_start_page | 1243 |
| container_title | Journal of diabetes science and technology |
| container_volume | 15 |
| creator | Srinivasan, Shylaja Ekhlaspour, Laya Cengiz, Eda |
| description | Closed-loop insulin delivery systems are fast becoming the standard of care in the management of type 1 diabetes and have led to significant improvements in diabetes management. Nevertheless, there is still room for improvement for the closed-loop systems to optimize treatment and meet target glycemic control. Adjunct treatments have been introduced as an alternative method to insulin-only treatment methods to overcome diabetes treatment challenges and improve clinical and patient reported outcomes during closed-loop treatment. The adjunct treatment agents mostly consist of medications that are already approved for type 2 diabetes treatment and aim to complete the missing physiologic factors, such as the entero-endocrine system, that regulate glycemia in addition to insulin. This paper will review many of these adjunct therapies, including the basic mechanisms of action, potential benefits, side effects, and the evidence supporting their use during closed-loop treatment. |
| doi_str_mv | 10.1177/19322968211032701 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8655279</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_19322968211032701</sage_id><sourcerecordid>2555967339</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-637566e002605ea6a5c265737130eb3266923377ecdad9b2f1ac8737eabc10223</originalsourceid><addsrcrecordid>eNp9UE1Lw0AQXUSxtfoDvEiOXlL3o7ubgAglaBUKvdTzstlM2y1JNmaTgv56E1pLRfA0M--9eTM8hG4JHhMi5QOJGaWxiCghmFGJyRka9ljYg-cn_QBdeb_FmE8iKS_RgE0Y4VTIIXqcZtu2NI3dQbDcQK0rCz5oXLCoGlvYLwiS3HnIwty5KpjlremmIHFlU7v8Gl2sdO7h5lBH6P3leZm8hvPF7C2ZzkMzYVETCia5EIAxFZiDFpobKrhkkjAMKaNCxJQxKcFkOotTuiLaRB0NOjUEU8pG6GnvW7VpAZmB7rrOVVXbQtefymmrfjOl3ai126lIcE5l3BncHwxq99GCb1RhvYE81yW41ivKOY-FZKyXkr3U1M77GlbHMwSrPnX1J_Vu5-70v-PGT8ydYLwXeL0GtXVtXXZ5_eP4DW7wibQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2555967339</pqid></control><display><type>article</type><title>Adjunctive Therapies to Optimize Closed-loop Glucose Control</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SAGE Journals</source><creator>Srinivasan, Shylaja ; Ekhlaspour, Laya ; Cengiz, Eda</creator><creatorcontrib>Srinivasan, Shylaja ; Ekhlaspour, Laya ; Cengiz, Eda</creatorcontrib><description>Closed-loop insulin delivery systems are fast becoming the standard of care in the management of type 1 diabetes and have led to significant improvements in diabetes management. Nevertheless, there is still room for improvement for the closed-loop systems to optimize treatment and meet target glycemic control. Adjunct treatments have been introduced as an alternative method to insulin-only treatment methods to overcome diabetes treatment challenges and improve clinical and patient reported outcomes during closed-loop treatment. The adjunct treatment agents mostly consist of medications that are already approved for type 2 diabetes treatment and aim to complete the missing physiologic factors, such as the entero-endocrine system, that regulate glycemia in addition to insulin. This paper will review many of these adjunct therapies, including the basic mechanisms of action, potential benefits, side effects, and the evidence supporting their use during closed-loop treatment.</description><identifier>ISSN: 1932-2968</identifier><identifier>EISSN: 1932-2968</identifier><identifier>EISSN: 1932-3107</identifier><identifier>DOI: 10.1177/19322968211032701</identifier><identifier>PMID: 34315267</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Algorithms ; Blood Glucose ; Combined Modality Therapy ; Diabetes Mellitus, Type 1 - drug therapy ; Diabetes Mellitus, Type 2 ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin Infusion Systems ; Pancreas, Artificial ; Special Section: The Artificial Pancreas: Improving Clinical Performance</subject><ispartof>Journal of diabetes science and technology, 2021-11, Vol.15 (6), p.1243-1251</ispartof><rights>2021 Diabetes Technology Society</rights><rights>2021 Diabetes Technology Society 2021 Diabetes Technology Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-637566e002605ea6a5c265737130eb3266923377ecdad9b2f1ac8737eabc10223</citedby><cites>FETCH-LOGICAL-c438t-637566e002605ea6a5c265737130eb3266923377ecdad9b2f1ac8737eabc10223</cites><orcidid>0000-0001-7992-9506 ; 0000-0002-3263-1419</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655279/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655279/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,21798,27901,27902,43597,43598,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34315267$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Srinivasan, Shylaja</creatorcontrib><creatorcontrib>Ekhlaspour, Laya</creatorcontrib><creatorcontrib>Cengiz, Eda</creatorcontrib><title>Adjunctive Therapies to Optimize Closed-loop Glucose Control</title><title>Journal of diabetes science and technology</title><addtitle>J Diabetes Sci Technol</addtitle><description>Closed-loop insulin delivery systems are fast becoming the standard of care in the management of type 1 diabetes and have led to significant improvements in diabetes management. Nevertheless, there is still room for improvement for the closed-loop systems to optimize treatment and meet target glycemic control. Adjunct treatments have been introduced as an alternative method to insulin-only treatment methods to overcome diabetes treatment challenges and improve clinical and patient reported outcomes during closed-loop treatment. The adjunct treatment agents mostly consist of medications that are already approved for type 2 diabetes treatment and aim to complete the missing physiologic factors, such as the entero-endocrine system, that regulate glycemia in addition to insulin. This paper will review many of these adjunct therapies, including the basic mechanisms of action, potential benefits, side effects, and the evidence supporting their use during closed-loop treatment.</description><subject>Algorithms</subject><subject>Blood Glucose</subject><subject>Combined Modality Therapy</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Diabetes Mellitus, Type 2</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Pancreas, Artificial</subject><subject>Special Section: The Artificial Pancreas: Improving Clinical Performance</subject><issn>1932-2968</issn><issn>1932-2968</issn><issn>1932-3107</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UE1Lw0AQXUSxtfoDvEiOXlL3o7ubgAglaBUKvdTzstlM2y1JNmaTgv56E1pLRfA0M--9eTM8hG4JHhMi5QOJGaWxiCghmFGJyRka9ljYg-cn_QBdeb_FmE8iKS_RgE0Y4VTIIXqcZtu2NI3dQbDcQK0rCz5oXLCoGlvYLwiS3HnIwty5KpjlremmIHFlU7v8Gl2sdO7h5lBH6P3leZm8hvPF7C2ZzkMzYVETCia5EIAxFZiDFpobKrhkkjAMKaNCxJQxKcFkOotTuiLaRB0NOjUEU8pG6GnvW7VpAZmB7rrOVVXbQtefymmrfjOl3ai126lIcE5l3BncHwxq99GCb1RhvYE81yW41ivKOY-FZKyXkr3U1M77GlbHMwSrPnX1J_Vu5-70v-PGT8ydYLwXeL0GtXVtXXZ5_eP4DW7wibQ</recordid><startdate>20211101</startdate><enddate>20211101</enddate><creator>Srinivasan, Shylaja</creator><creator>Ekhlaspour, Laya</creator><creator>Cengiz, Eda</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7992-9506</orcidid><orcidid>https://orcid.org/0000-0002-3263-1419</orcidid></search><sort><creationdate>20211101</creationdate><title>Adjunctive Therapies to Optimize Closed-loop Glucose Control</title><author>Srinivasan, Shylaja ; Ekhlaspour, Laya ; Cengiz, Eda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-637566e002605ea6a5c265737130eb3266923377ecdad9b2f1ac8737eabc10223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Algorithms</topic><topic>Blood Glucose</topic><topic>Combined Modality Therapy</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Diabetes Mellitus, Type 2</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Pancreas, Artificial</topic><topic>Special Section: The Artificial Pancreas: Improving Clinical Performance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Srinivasan, Shylaja</creatorcontrib><creatorcontrib>Ekhlaspour, Laya</creatorcontrib><creatorcontrib>Cengiz, Eda</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of diabetes science and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Srinivasan, Shylaja</au><au>Ekhlaspour, Laya</au><au>Cengiz, Eda</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjunctive Therapies to Optimize Closed-loop Glucose Control</atitle><jtitle>Journal of diabetes science and technology</jtitle><addtitle>J Diabetes Sci Technol</addtitle><date>2021-11-01</date><risdate>2021</risdate><volume>15</volume><issue>6</issue><spage>1243</spage><epage>1251</epage><pages>1243-1251</pages><issn>1932-2968</issn><eissn>1932-2968</eissn><eissn>1932-3107</eissn><abstract>Closed-loop insulin delivery systems are fast becoming the standard of care in the management of type 1 diabetes and have led to significant improvements in diabetes management. Nevertheless, there is still room for improvement for the closed-loop systems to optimize treatment and meet target glycemic control. Adjunct treatments have been introduced as an alternative method to insulin-only treatment methods to overcome diabetes treatment challenges and improve clinical and patient reported outcomes during closed-loop treatment. The adjunct treatment agents mostly consist of medications that are already approved for type 2 diabetes treatment and aim to complete the missing physiologic factors, such as the entero-endocrine system, that regulate glycemia in addition to insulin. This paper will review many of these adjunct therapies, including the basic mechanisms of action, potential benefits, side effects, and the evidence supporting their use during closed-loop treatment.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>34315267</pmid><doi>10.1177/19322968211032701</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7992-9506</orcidid><orcidid>https://orcid.org/0000-0002-3263-1419</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-2968 |
| ispartof | Journal of diabetes science and technology, 2021-11, Vol.15 (6), p.1243-1251 |
| issn | 1932-2968 1932-2968 1932-3107 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8655279 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; SAGE Journals |
| subjects | Algorithms Blood Glucose Combined Modality Therapy Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 2 Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Pancreas, Artificial Special Section: The Artificial Pancreas: Improving Clinical Performance |
| title | Adjunctive Therapies to Optimize Closed-loop Glucose Control |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A57%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjunctive%20Therapies%20to%20Optimize%20Closed-loop%20Glucose%20Control&rft.jtitle=Journal%20of%20diabetes%20science%20and%20technology&rft.au=Srinivasan,%20Shylaja&rft.date=2021-11-01&rft.volume=15&rft.issue=6&rft.spage=1243&rft.epage=1251&rft.pages=1243-1251&rft.issn=1932-2968&rft.eissn=1932-2968&rft_id=info:doi/10.1177/19322968211032701&rft_dat=%3Cproquest_pubme%3E2555967339%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2555967339&rft_id=info:pmid/34315267&rft_sage_id=10.1177_19322968211032701&rfr_iscdi=true |